一、独立董事基本情况 赵锐，女，1965 年出生，中国国籍，无永久境外居留权，中共党员，主任 检验师，1989 年本科毕业于北华大学医学检验系，获得医学学士学位；1989 年 8 月至 2020 年 4 月，在北京电力医院工作，曾任北京电力医院检验科主任及感 染疾控管理处处长。主持或主要负责科研立项 30 余项；发表 SCI 及核心期刊学 术论文 70 余篇；副主编及参编撰写专业书籍 8 本；曾参与制定中华人民共和国 卫生行业标准 2 项，共识 1 项。现任北京电力医院主任。 本人不在公司担任除独立董事外的其他职务，与公司及其主要股东不存在直 接或者间接利害关系，或者其他可能影响本人独立客观判断的关系，不存在影响 独立性的情况。 博爱新开源医疗科技集团股份有限公司 2024 年度独立董事述职报告（赵锐） 各位股东及股东代表: 报告期内，本人作为博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）独立董事，严格按照《公司法》《证券法》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》 等法律法规和规范性文件以及《公司章程》《独立董事制度》的相关规定和要求 ...

新开源 舆情管理制度 博爱新开源医疗科技集团股份有限公司 舆情管理制度 新开源 舆情管理制度 第一章 总则 二○二五年四月 1 第一条 为提高博爱新开源医疗科技集团股份有限公司（以下简称"公司"） 应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合 法权益，根据相关法律、法规和规范性文件的规定及《博爱新开源医疗科技集团 股份有限公司章程》 （以下简称"《公司章程》"），结合公司实际情况，制定 本制度。 第二条 本制度所称"舆情"包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较 大影响的事件信息。 第三条 本制度适用于公司及公司全资子公司、控股子公司（以下统称"子公 司"）。 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第五条 公司成立应对舆情管 ...

博爱新开源医疗科技集团股份有限公司 2024 年度独立董事述职报告（方拥军） 各位股东及股东代表: 报告期内，本人作为博爱新开源医疗科技集团股份有限公司（以下简称"公 司"）独立董事，严格按照《公司法》《证券法》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》 等法律法规和规范性文件以及《公司章程》《独立董事制度》的相关规定和要求， 本着客观、公正、独立的原则，勤勉、尽责、忠实地履行职务，积极出席相关会 议，对公司审议决策的重大事项均要求提供相关资料进行认真审核，必要时向公 司相关部门和人员询问，并利用自身的专业知识，客观、审慎地行使表决权，努 力维护了公司整体利益和广大中小股东的合法权益，为公司的规范运作和健康发 展发挥了积极作用。现将本人 2024 年度履行独立董事职责的基本情况报告如下： 一、独立董事基本情况 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《上市公司独立董事管理办法》《独立董事制度》的规定，本人就公司 2024 年度以下事项发表了意见，切实履行了独立董事的监督职责： | 序号 | 召开日 | 会议 ...

Financial Performance - The company's revenue for Q1 2025 was ¥324,863,000.55, a decrease of 17.69% compared to ¥394,687,984.97 in the same period last year[5] - Net profit attributable to shareholders was ¥80,420,300.50, down 33.75% from ¥121,387,401.37 year-on-year[5] - Basic and diluted earnings per share were both ¥0.17, reflecting a decline of 32.00% compared to ¥0.25 in the same quarter last year[5] - Operating profit fell to ¥90,839,459.16 compared to ¥143,346,308.66 in the previous period, a decrease of about 36.6%[24] - Net profit for the period was ¥79,771,301.77, down from ¥120,924,966.70, reflecting a decline of approximately 34.1%[24] - Total operating revenue decreased to ¥324,863,000.55 from ¥394,687,984.97, representing a decline of approximately 17.6% year-over-year[23] Cash Flow - The net cash flow from operating activities decreased by 63.26% to ¥47,514,176.29 from ¥129,324,196.47 in the previous year[5] - Operating cash inflow decreased slightly by 2.10% to ¥351,655,897.01 from ¥359,217,162.55 in the previous year[10] - Cash inflow from financing activities increased by 27,140.00% to 245,160,000.00, mainly due to an increase in cash received from borrowings[11] - Cash inflow from investment activities was $290,000,000.00, significantly higher than $913,188.00 in the previous period[26] - Net cash flow from investment activities was $200,806,519.83, a turnaround from a negative $138,217,291.74 in the previous period[26] - Cash received from operating activities was $351,655,897.01, slightly down from $359,217,162.55 in the previous period[26] - Total cash outflow from operating activities was $304,141,720.72, an increase from $229,892,966.08 in the previous period[26] - Cash received from tax refunds was $19,134,427.09, a significant increase from $1,124,453.20 in the previous period[26] Assets and Liabilities - Total assets increased by 2.86% to ¥4,497,035,940.74 from ¥4,372,054,795.55 at the end of the previous year[5] - Total current assets increased to 1,833,434,146.75 from 1,511,752,553.06, reflecting a significant growth in liquidity[19] - Cash and cash equivalents rose to 841,890,471.25 from 547,327,751.31, indicating improved cash position[19] - Total liabilities increased to ¥811,022,838.61 from ¥764,369,013.92, reflecting a growth of about 6.1%[21] - The company's equity attributable to shareholders increased to ¥3,716,911,036.74 from ¥3,637,934,717.51, a rise of approximately 2.2%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 22,718, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Wang Donghu, holds 8.68% of shares, amounting to 42,095,222 shares, with 27,350,000 shares pledged[13] - The total number of restricted shares at the end of the period remained at 36,226,876, indicating stable management of shareholding[16] - The company has no preferred shareholders and no changes in restricted shares during the reporting period[15] Research and Development - Research and development expenses rose by 57.65% to ¥21,533,233.95 from ¥13,658,788.28 in the same quarter last year[10] - Research and development expenses increased to ¥21,533,233.95 from ¥13,658,788.28, marking a rise of about 57.5% year-over-year[24] Borrowings and Financing - The company reported a significant increase in long-term borrowings by 181.91%, reaching ¥58,114,509.38 compared to ¥20,614,509.38 at the end of the previous year[10] - The company reported a significant increase in cash outflow from financing activities, which rose by 1,675.58% to 206,497,499.56[11] Future Outlook - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[23]

Financial Performance - The company reported a revenue of 300 million CNY for the last quarter, representing a 15% increase year-over-year[14]. - The company's operating revenue for 2024 was CNY 1,606,320,028.31, representing a 1.45% increase compared to CNY 1,583,417,842.97 in 2023[19]. - Net profit attributable to shareholders decreased by 29.07% to CNY 349,680,187.51 in 2024 from CNY 493,027,339.92 in 2023[19]. - Cash flow from operating activities decreased by 47.56% to CNY 256,030,360.20 in 2024 from CNY 488,252,026.37 in 2023[19]. - Basic earnings per share fell by 30.48% to CNY 0.73 in 2024 from CNY 1.05 in 2023[19]. - The company reported a significant decline in quarterly net profit, with Q4 2024 net profit at CNY 38,437,017.65, down from CNY 121,387,401.37 in Q1 2024[21]. - The overall business performance remains strong, with no significant changes in the main business and products during the reporting period[43]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 2.5 RMB per 10 shares to all shareholders, based on a total of 484,700,005 shares[4]. Market Expansion and Growth Strategies - The company expects a revenue guidance of 350 million CNY for the next quarter, which would be a 16.67% increase from the current quarter[14]. - Market expansion plans include entering two new provinces, projected to increase market share by 5%[14]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 100 million CNY allocated for this purpose[14]. - A new strategic partnership has been established with a leading healthcare provider to improve service delivery and patient outcomes[14]. - The company aims to enhance its digital marketing efforts, with a planned increase in budget by 25% to boost online engagement[14]. - Future projections suggest continued growth in revenue, with expectations of maintaining or increasing current performance levels[52]. - The company is exploring new product development and technological advancements to enhance its market position[52]. - The company has outlined plans for market expansion, particularly in the healthcare sector, to capitalize on emerging opportunities[52]. Research and Development - The company is investing 10 million CNY in R&D for new technologies aimed at enhancing diagnostic capabilities[14]. - The company has established a strong R&D capability, focusing on technological and product innovation, and is one of the earliest enterprises in China to industrialize PVP series products[46]. - The company has invested in several R&D companies, including Guangzhou Weirong Medical Technology Co., Ltd., to enhance its capabilities in precision diagnostics and treatment[37]. - The company is focusing on expanding its market reach through the development of new dental technologies and products, aiming to enhance user experience and satisfaction[29][30][32][33][34][36][37][38][39][40]. - The company is actively pursuing technology research and product development projects to innovate within the healthcare sector[62]. - The company has a strong focus on research and development, particularly in the field of pharmaceutical excipients, to enhance its product offerings and market competitiveness[81]. Product Development and Innovation - New product launches are anticipated to contribute an additional 50 million CNY in revenue over the next fiscal year[14]. - The company has developed a fully autonomous CAR-T cell production base, which is the only one in China with complete intellectual property rights[36]. - The company has introduced a new line of dental care products, projected to generate an additional $5 million in revenue within the first year[60]. - The company has developed a new acrylic-maleic acid copolymer sodium salt product with independent intellectual property rights, which contains high-density carboxyl groups and can be used as a chelating agent and dispersant for water scale prevention[118]. - The introduction of intelligent classification algorithms aims to improve the efficiency and accuracy of cervical cancer screening[119]. - The company has developed a reagent kit for single-cell nuclear suspension preparation, increasing product sales revenue and expanding service range[121]. Risk Management and Compliance - The company has detailed potential risks and countermeasures in the "Management Discussion and Analysis" section of the report[4]. - The report emphasizes the commitment of the board and management to ensure the accuracy and completeness of the financial report[4]. - The company has established a quality management system compliant with ISO 9001:2015 standards, applicable to the production of pharmaceutical excipients, ensuring product quality and regulatory compliance[78]. - The company has received a certification for its occupational health and safety management system, compliant with ISO 45001:2018, enhancing workplace safety standards[79]. Asset Management and Investments - Total assets increased by 8.77% to CNY 4,372,054,795.55 at the end of 2024 from CNY 4,019,691,116.69 at the end of 2023[19]. - The company has established a strong brand reputation in the chemical sector, making it difficult for new entrants to replicate its success quickly[49]. - The company has secured land use rights through various certificates, ensuring legal compliance and operational legitimacy[51]. - The company has multiple industrial land use rights with expiration dates ranging from 2051 to 2060, indicating long-term operational stability[51]. User Engagement and Customer Base - User data indicates a growth in active users by 20% compared to the previous quarter, reaching 1.2 million active users[14]. - The user base expanded to 1.5 million active users, representing a 20% increase compared to the previous quarter[56]. - The company reported a significant increase in user data, with a growth rate of 25% year-over-year in the last quarter[57]. Sustainability and Corporate Responsibility - The company is focusing on sustainability initiatives, with a goal to reduce carbon emissions by 25% over the next five years[57]. - The company has initiated a sustainability program aimed at reducing operational costs by 15% over the next three years[62]. - The company has completed a third-party audit of greenhouse gas emissions[99]. Regulatory Approvals and Certifications - The company has obtained various international certifications for its products, including the European Pharmacopoeia suitability certificates for Povidone K30, K25, and K90, valid until April 13, 2027, June 9, 2028, and June 23, 2028 respectively[81]. - Heer Medical received multiple product approvals, including a cell preservation solution and a fully automated DNA quantification system, with effective dates extending to 2025 and 2026[82][83]. - The company has received high-tech enterprise certification in multiple provinces, including Henan and Hunan, with certificates valid for three years, enhancing its market credibility and potential for tax benefits[77].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Xin Kai Yuan, a company in the chemical products and precision medical industry, with a current stock price of 14.92 yuan and a market capitalization of 7.232 billion yuan [1][2] - Xin Kai Yuan's rolling price-to-earnings (PE) ratio stands at 18.11, significantly lower than the industry average PE of 50.88 and the median PE of 35.81, indicating a relatively undervalued position within its sector [1][2] - As of March 31, 2025, Xin Kai Yuan has 22,700 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder, reflecting a decrease of 1,100 shareholders since the last report [1] Group 2 - The latest financial results for Xin Kai Yuan show a revenue of 1.111 billion yuan for the third quarter of 2024, representing a year-on-year decline of 7.92%, while net profit decreased by 23.13% to 311 million yuan, with a gross profit margin of 52.10% [1] - The company's main business segments include fine chemicals and precision medicine, with key products such as PVPK30, PVP-I, and various diagnostic services, indicating a diverse product portfolio [1]

近日，Meta发布了开源模型Llama家族的全新AI模型系列Llama4，其中包括Llama4Scout、 Llama4Maverick和Llama4Behemoth。但规模最大、性能最强的Llama4Behemoth模型仍在训练中。据 Meta透露，这款"庞然大物"不仅在性能上碾压同类AI产品，还将作为"新模型的训练基石"。同时Meta表 示，Llama4也是同类产品中多模态性最好的模型。 点评：Meta推出Llama4系列AI模型，特别是Llama4Behemoth的预告，显示了其在人工智能领域的研发 实力和领先地位。这一动作可能提升市场对其长期技术发展的信心，对AI领域的企业产生示范效应。 Llama4的多模态优势预示着更广泛的应用前景，可能促使行业对AI解决方案的需求增长，对相关板块 形成积极影响。 NO.3特斯拉FSD系统正在等待欧洲监管批准 近日，特斯拉在其欧洲和中东地区的官方账号上发布了一段FSD系统测试视频。账号发文称："FSD在 欧洲接受监督，等待监管部门批准。"尽管特斯拉计划今年在欧洲和中东的多个新市场推出该软件，但 视频中明确指出，目前的驾驶测试仍处于"工程测试阶段"，并非正式在这些市场 ...

证券代码：300109 证券简称：新开源 公告编号：2025-005 博爱新开源医疗科技集团股份有限公司 关于公司董事收到行政处罚事先告知书的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 博爱新开源医疗科技集团股份有限公司（以下简称"公司""新开源"）于 2025年1月21日披露了《关于公司董事收到立案告知书的公告》（公告编号： 2025-002），公司董事赵威先生收到中国证券监督管理委员会（以下简称"中国 证监会"）的《立案告知书》（编号：证监立案字0122025004号），根据《中华 人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决 定对赵威先生因涉嫌短线交易予以立案。 公司近日收到赵威先生的通知，获悉其已收到中国证监会河南监管局的《行 政处罚事先告知书》（〔2025〕1号）（以下简称《告知书》），现就具体内容 公告如下： 一、《行政处罚事先告知书》主要内容 赵威先生担任公司董事期间，其近亲属赵天存在六个月买卖"新开源"股票 行为，导致赵威涉嫌违反《中华人民共和国证券法》第四十四条第一款、第二款 的规定，构成《证券法》第一百八十九 ...

Group 1 - The core viewpoint of the articles indicates that Xin Kai Yuan's stock closed at 16.96 yuan, down 1.17%, with a rolling PE ratio of 20.58 times and a total market value of 8.221 billion yuan [1] - The average PE ratio for the chemical products industry is 45.23 times, with a median of 34.79 times, placing Xin Kai Yuan at the 66th position in the industry ranking [1] - In terms of capital flow, Xin Kai Yuan experienced a net outflow of 12.0542 million yuan on March 31, with a total outflow of 55.3879 million yuan over the past five days [1] Group 2 - Xin Kai Yuan Medical Technology Group Co., Ltd. primarily operates in fine chemicals and precision medicine, with key products including PVPK30, PVP-I, and various precision medical services [1] - The latest financial results for the third quarter of 2024 show that the company achieved an operating income of 1.111 billion yuan, a year-on-year decrease of 7.92%, and a net profit of 311 million yuan, down 23.13% year-on-year, with a gross profit margin of 52.10% [1]

3月27日，新开源今日收盘17.92元，上涨8.02%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到21.75倍，创196天以来新低，总市值86.86亿元。 从行业市盈率排名来看，公司所处的化学制品行业市盈率平均47.15倍，行业中值38.11倍，新开源排名 第67位。 最新一期业绩显示，2024年三季报，公司实现营业收入11.11亿元，同比-7.92%；净利润3.11亿元，同 比-23.13%，销售毛利率52.10%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)67新开源21.7517.622.4886.86亿行业平均 47.1551.652.9881.01亿行业中值38.1138.252.3141.70亿1宏柏新材-5903.6759.131.9838.42亿2北化股 份-2226.97108.492.1560.23亿3锦鸡股份-843.15246.712.3039.10亿4渝三峡A-658.00-69.121.9324.06亿5富 淼科技-342.63-342.631.2416.86亿6石大胜华-184.58396.251.9074.20亿7信德新材-151.8693.341 ...